MediWound
42 Ha'Yarkon Street
Yavne
Tel: 972-8-9324010
Fax: 972-8-9324011
185 articles about MediWound
-
MediWound Announces Positive Outcome of Interim Assessment for its EscharEx U.S. Phase 2 Adaptive Design Study
7/28/2021
MediWound Ltd. announced a positive outcome from a planned interim sample size re-estimation of its ongoing EscharEx® U.S. phase 2 adaptive design study for the treatment of venous leg ulcers, designed to assess the safety and efficacy of EscharEx compared to gel vehicle and non-surgical standard-of-care.
-
Clinical Catch-Up: July 19-23
7/26/2021
It was another busy week for clinical trial updates. Here’s a look at some including Mesoblast Limited, CytoDyn, Magenta Therapeutics and more. -
MediWound Announces Initiation of U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
7/26/2021
MediWound Ltd., a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutics solutions for tissue repair and regeneration, announced initiation of its phase I/II study of MW005 for the treatment of low-risk Basal Cell Carcinoma.
-
MediWound Announces Positive Topline Results from Phase 3 Pediatric Study (CIDS) of NexoBrid for Eschar Removal of Severe Thermal Burns
7/20/2021
MediWound Ltd., a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutics solutions for tissue repair and regeneration, announced positive topline results from its pivotal phase 3 pediatric clinical study with NexoBrid® to treat children with severe thermal burns, evaluating the efficacy and safety compared with standard-of-care.
-
MediWound Announces Peer-Reviewed Paper Detailing EscharEx Phase 2 Randomized Control Trial Results Published in the Online Wound Repair and Regeneration Journal
7/9/2021
MediWound Ltd. today announced that a peer-reviewed publication, detailing the results of a phase 2 randomized control trial of its wound debriding product candidate EscharEx®, has been published in the Wound Repair and Regeneration Journal. An interim assessment of EscharEx's U.S. phase 2 adaptive design study for the treatment of venous leg ulcers (VLUs) is expected by end of July 2021.
-
MediWound Receives Complete Response Letter from U.S. FDA for NexoBrid Biologics License ApplicationCompany Remains Committed to Working with FDA Toward a Potential Approval for this Important Therapy
6/29/2021
MediWound Ltd. today announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) seeking approval of NexoBrid ® for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns.
-
MediWound Announces Peer-Reviewed Paper of a Case Series Report of Basal Cell Carcinoma Published in the Open Dermatology Journal
6/7/2021
MediWound Ltd., a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, announced that a peer-reviewed publication of a case series report of basal cell carcinoma destruction by a concentrate of proteolytic enzymes enriched in bromelain has been published in the Open Dermatology Journal.
-
MediWound to Report First Quarter 2021 Financial Results and Host a Conference Call and Webcast on May 5, 2021
4/26/2021
MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the first quarter ended March 31, 2021 at 7:00 am Eastern Time on Wednesday, May 5, 2021. Following the release, MediWound's management will host a conference call and live webcast on Wednesday, May 5, 2021
-
MediWound Hosting Analyst Day Webinar on EscharEx – Enzymatic Debridement Agent for Chronic Wounds
3/24/2021
MediWound Ltd., a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, announced that it will host an analyst day webinar on EscharEx®, MediWound’s enzymatic debridement agent for chronic wounds, on Tuesday, March 30, 2021 at 10am Eastern Time.
-
MediWound to Participate in Upcoming March 2021 Investment Conferences
2/25/2021
MediWound Ltd., a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, announced that the Company will present at the following virtual investor conferences in March 2021:
-
MediWound Reports Fourth Quarter and Full-Year 2020 Financial Results
2/25/2021
MediWound Ltd., a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, announced financial results for the fourth quarter and full-year ended December 31, 2020.
-
MediWound to Report Fourth Quarter and Fiscal 2020 Financial Results and Host a Conference Call and Webcast on February 25, 2021
2/16/2021
- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the fourth quarter and year ended December 31, 2020 at 7:00 am Eastern Time on Thursday, February 25, 2021.
-
Clinical Catch-Up: January 11-15
1/18/2021
The year is starting to pick up in terms of clinical trial announcements. Here’s a look at last week’s news. -
MediWound Provides Progress Update on Its EscharEx Clinical Development Program
1/11/2021
MediWound Ltd., a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, provided an update on its EscharEx® clinical development program.
-
MediWound to Participate in Upcoming Investor Conferences in January 2021
1/5/2021
MediWound Ltd., a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announced that it will participate in the forthcoming LifeSci Partners 10th Annual Corporate Access Event and the H.C. Wainwright BioConnect 2021 Conference.
-
Successful Completion of In-Vivo Head-to-Head Comparator Study of EscharEx versus a Commercial Enzymatic Debridement AgentData to be Published in a Peer-Reviewed Journal in First Half 2021
12/21/2020
MediWound Ltd. announced the successful completion of a pre-clinical study designed to evaluate the debridement efficacy of EscharEx®, a novel bromelain-based enzymatic debridement agent, in a porcine hard-to-heal wound model, and compare its efficacy with an FDA approved and commercially available collagenase enzymatic debridement agent.
-
MediWound Continues Global Expansion with Distribution Agreement for NexoBrid in United Arab Emirates with Ghassan Aboud Group
12/14/2020
MediWound Ltd. announced it has further expanded its NexoBrid® global presence and entered the Middle Eastern markets with the signing of a distribution agreement granting Ghassan Aboud Group, an international conglomerate based in the United Arab Emirates, an exclusive right to market and distribute NexoBrid in UAE for the treatment of severe burns.
-
MediWound Reports Third Quarter 2020 Financial Results
11/10/2020
MediWound Ltd., a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announced financial results for the third quarter ended September 30, 2020.
-
MediWound Completes Enrollment Stage of its NexoBrid Phase 3 Pediatric StudyTop-line Data is Expected in the Second Half of 2021
10/28/2020
MediWound Ltd., a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announced it has completed the enrollment stage of its NexoBrid® Phase 3 pediatric clinical study.
-
BioSpace Global Roundup, Sept. 17
9/17/2020
Companies from across the globe provide updates on their businesses and pipelines.